Innovus Pharma to Present at Rodman & Renshaw 19 th Annual Global
Investment Conference
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage
pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today
announced that Dr. Bassam Damaj, President & Chief Executive Officer and Rauly Gutierrez, Vice President, Finance will present
at the 2017 Rodman & Renshaw 19th Annual Global Investment Conference, on Tuesday, September 12th. Dr.
Damaj will present an update on the Company’s growing revenues, the launch of new products, including its FlutiCare™ product
expected to launch in the fourth quarter of 2017, and its other business plans.
Dr. Damaj and Mr. Gutierrez will be meeting with members of the investment community during one-on-one meetings at the
conference as well. The corporate presentation will be available for download on the Innovus Pharma web site (www.innovuspharma.com).
About Conference Presentation Time
Event: Rodman & Renshaw 19th Annual Global Investment Conference
Date: Tuesday, September 12, 2017
Time: 10:25 AM-10:50 AM EDT
Location: The Adams Room, 4th Floor, Lotte New York Palace Hotel, 455 Madison Ave, New York, NY 10022
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the
commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve
men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and
packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial
partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our
on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and
branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing
prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com ; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; and www.apeaz.com .
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information
contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties
that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the
Company, including, but not limited to, projected revenues from the sale of its products, estimated market for its products, and
statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are
cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent
filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the
SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
Emerging Markets Consulting, LLC
James S. Painter III, 407-340-0226
jamespainter@emergingmarketsllc.com
or
Chesapeake Group
410-825-3930
info@chesapeakegp.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170828005325/en/